Disclosures for "Risdiplam as Effective Bridge Therapy Before Gene Replacement in Presymptomatic Infants with SMA"
-
Author has nothing to disclose
-
Dr. Lemska has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. Dr. Lemska has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen.